|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAZ |
Gene summary for TAZ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAZ | Gene ID | 6901 |
| Gene name | tafazzin, phospholipid-lysophospholipid transacylase | |
| Gene Alias | BTHS | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A0S2Z4K0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6901 | TAZ | LZE2T | Human | Esophagus | ESCC | 3.13e-04 | 4.29e-01 | 0.082 |
| 6901 | TAZ | LZE4T | Human | Esophagus | ESCC | 8.51e-04 | 1.05e-01 | 0.0811 |
| 6901 | TAZ | LZE7T | Human | Esophagus | ESCC | 4.95e-08 | 2.12e-01 | 0.0667 |
| 6901 | TAZ | LZE20T | Human | Esophagus | ESCC | 4.08e-05 | 1.05e-01 | 0.0662 |
| 6901 | TAZ | LZE22D1 | Human | Esophagus | HGIN | 2.17e-10 | 3.89e-01 | 0.0595 |
| 6901 | TAZ | LZE22T | Human | Esophagus | ESCC | 2.24e-04 | 2.15e-01 | 0.068 |
| 6901 | TAZ | LZE24T | Human | Esophagus | ESCC | 4.52e-31 | 6.33e-01 | 0.0596 |
| 6901 | TAZ | LZE21T | Human | Esophagus | ESCC | 4.09e-07 | 2.85e-01 | 0.0655 |
| 6901 | TAZ | P1T-E | Human | Esophagus | ESCC | 1.04e-17 | 8.14e-01 | 0.0875 |
| 6901 | TAZ | P2T-E | Human | Esophagus | ESCC | 1.44e-25 | 4.15e-01 | 0.1177 |
| 6901 | TAZ | P4T-E | Human | Esophagus | ESCC | 9.21e-11 | 3.38e-01 | 0.1323 |
| 6901 | TAZ | P5T-E | Human | Esophagus | ESCC | 2.19e-14 | 2.48e-01 | 0.1327 |
| 6901 | TAZ | P8T-E | Human | Esophagus | ESCC | 4.80e-14 | 2.39e-01 | 0.0889 |
| 6901 | TAZ | P9T-E | Human | Esophagus | ESCC | 1.67e-19 | 3.48e-01 | 0.1131 |
| 6901 | TAZ | P10T-E | Human | Esophagus | ESCC | 1.22e-17 | 3.24e-01 | 0.116 |
| 6901 | TAZ | P11T-E | Human | Esophagus | ESCC | 4.76e-06 | 3.13e-01 | 0.1426 |
| 6901 | TAZ | P12T-E | Human | Esophagus | ESCC | 1.45e-27 | 4.75e-01 | 0.1122 |
| 6901 | TAZ | P15T-E | Human | Esophagus | ESCC | 7.14e-11 | 2.63e-01 | 0.1149 |
| 6901 | TAZ | P16T-E | Human | Esophagus | ESCC | 1.01e-04 | 1.47e-01 | 0.1153 |
| 6901 | TAZ | P17T-E | Human | Esophagus | ESCC | 1.81e-07 | 2.17e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAZ | SNV | Missense_Mutation | c.452G>A | p.Arg151Lys | p.R151K | Q16635 | protein_coding | tolerated_low_confidence(0.38) | benign(0) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| TAZ | SNV | Missense_Mutation | novel | c.571C>T | p.Arg191Cys | p.R191C | Q16635 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TAZ | SNV | Missense_Mutation | novel | c.316N>G | p.Lys106Glu | p.K106E | Q16635 | protein_coding | deleterious(0.04) | benign(0.339) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TAZ | SNV | Missense_Mutation | c.773N>T | p.Ser258Leu | p.S258L | Q16635 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| TAZ | SNV | Missense_Mutation | novel | c.388N>A | p.Ala130Thr | p.A130T | Q16635 | protein_coding | tolerated_low_confidence(0.49) | benign(0.169) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TAZ | SNV | Missense_Mutation | c.799A>G | p.Thr267Ala | p.T267A | Q16635 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TAZ | SNV | Missense_Mutation | rs375663114 | c.562G>A | p.Glu188Lys | p.E188K | Q16635 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-DC-6682-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TAZ | SNV | Missense_Mutation | c.551N>G | p.Asn184Ser | p.N184S | Q16635 | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TAZ | SNV | Missense_Mutation | novel | c.602N>T | p.Ala201Val | p.A201V | Q16635 | protein_coding | tolerated(0.2) | possibly_damaging(0.802) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| TAZ | SNV | Missense_Mutation | novel | c.336N>A | p.Phe112Leu | p.F112L | Q16635 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |